Real-time monitoring the spatiotemporal dynamics of intracellular cGMP in vascular smooth muscle cells

Methods in Molecular Biology

Volumn 1020, Issue , 2013, Pages 131-145

  Held, Kara F ^a   Dostmann, Wolfgang R ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Biosensors; cGMP; Live cell imaging; Nitric oxide; Vascular smooth muscle

Indexed keywords

CYCLIC GMP; PHOSPHODIESTERASE V;

ANIMAL CELL; ARTICLE; BIOSENSOR; CELL LEVEL; FLUORESCENCE RESONANCE ENERGY TRANSFER; IMMUNOBLOTTING; INTRACELLULAR SIGNALING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

MAMMALIA;

EID: 84883195444     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-459-3_8     Document Type: Article

References (56)

1. Friebe A, Koesling D (2003) Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 93(2):96-105
2. Kuhn M (2003) Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res 93(8):700-709
3. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511
4. Francis SH, Blount MA, Zoraghi R et al (2005) Molecular properties of mammalian proteins that interact with cGMP: Protein kinases, cation channels, phosphodiesterases, and multidrug anion transporters. Front Biosci 10:2097-2117
5. Kemp-Harper B, Schmidt HH (2009) cGMP in the vasculature. Handb Exp Pharmacol 191:447-467
6. Alverdi V, Mazon H, Versluis C et al (2008) cGMP-binding prepares PKG for substrate binding by disclosing the C-terminal domain. J Mol Biol 375(5):1380-1393
7. Scholten A, Fuss H, Heck AJ et al (2007) The hinge region operates as a stability switch in cGMP-dependent protein kinase I alpha. FEBS J 274(9):2274-2286
8. Surks HK, Mochizuki N, Kasai Y et al (1999) Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase Ialpha. Science 286(5444):1583-1587
9. Tang KM, Wang GR, Lu P et al (2003) Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 9(12):1506-1512
10. Wooldridge AA, MacDonald JA, Erdodi F et al (2004) Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of serine 695 in response to cyclic nucleotides. J Biol Chem 279(33):34496-34504
11. Sun X, Kaltenbronn KM, Steinberg TH et al (2005) RGS2 is a mediator of nitric oxide action on blood pressure and vasoconstrictor signaling. Mol Pharmacol 67(3):631-639
12. Schlossmann J, Ammendola A, Ashman K et al (2000) Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Ibeta. Nature 404(6774): 197-201
13. Geiselhoringer A, Werner M, Sigl K et al (2004) IRAG is essential for relaxation of receptor-triggered smooth muscle contraction by cGMP kinase. EMBO J 23(21):4222-4231
14. Lalli MJ, Shimizu S, Sutliff RL et al (1999) [Ca2+]i homeostasis and cyclic nucleotide relaxation in aorta of phospholamban-deficient mice. Am J Physiol 277(3 Pt 2):H963-H970
15. Sausbier M, Schubert R, Voigt V et al (2000) Mechanisms of NO/cGMP-dependent vasorelaxation. Circ Res 87(9):825-830
16. Ellerbroek SM, Wennerberg K, Burridge K (2003) Serine phosphorylation negatively regulates RhoA in vivo. J Biol Chem 278(21): 19023-19031
17. Weber S, Bernhard D, Lukowski R et al (2007) Rescue of cGMP kinase I knockout mice by smooth muscle specific expression of either isozyme. Circ Res 101(11):1096-1103
18. Rybalkin SD, Bornfeldt KE, Sonnenburg WK et al (1997) Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest 100(10):2611-2621
19. Rybalkin SD, Rybalkina IG, Feil R et al (2002) Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 277(5):3310-3317
20. Thomas MK, Francis SH, Corbin JD (1990) Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. J Biol Chem 265(25): 14971-14978
21. Corbin JD, Turko IV, Beasley A et al (2000) Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 267(9):2760-2767
22. Francis SH, Poteet-Smith C, Busch JL et al (2002) Mechanisms of autoinhibition in cyclic nucleotide-dependent protein kinases. Front Biosci 7:d580-d592
23. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M et al (2003) PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 22(3):469-478
24. Zoraghi R, Bessay EP, Corbin JD et al (2005) Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem 280(12): 12051-12063
25. Omori K, Kotera J (2007) Overview of PDEs and their regulation. Circ Res 100(3):309-327
26. Held KF, Dostmann WR (2012) Subnanomolar sensitivity of nitric oxide mediated regulation of cGMP and vasomotor reactivity in vascular smooth muscle. Front Pharmacol 3:130
27. Halvey EJ, Vernon J, Roy B et al (2009) Mechanisms of activity-dependent plasticity in cellular no-cGMP signaling. J Biol Chem 284(38):25630-25641
28. Batchelor AM, Bartus K, Reynell C et al (2010) Exquisite sensitivity to subsecond, picomolar nitric oxide transients conferred on cells by guanylyl cyclase-coupled receptors. Proc Natl Acad Sci USA107(51):22060-22065
29. Bellamy TC, Wood J, Goodwin DA et al (2000) Rapid desensitization of the nitric oxide receptor, soluble guanylyl cyclase, underlies diversity of cellular cGMP responses. Proc Natl Acad Sci USA97(6):2928-2933
30. Steiner AL, Parker CW, Kipnis DM (1972) Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J Biol Chem 247(4):1106-1113
31. Wehmann RE, Blonde L, Steiner AL (1972) Simultaneous radioimmunoassay for the measurement of adenosine 3 ¢, 5 ¢ -monophosphate and guanosine 3 ¢, 5 ¢ -monophosphate. Endocrinology 90(1):330-335
32. Lakowicz JR, Gryczynski I, Gryczynski Z et al (1999) Anisotropy-based sensing with reference fl uorophores. Anal Biochem 267(2): 397-405
33. Heim R, Prasher DC, Tsien RY (1994) Wavelength mutations and posttranslational autoxidation of green fl uorescent protein. Proc Natl Acad Sci USA91(26):12501-12504
34. Zukin RS, Hartig PR, Koshland DE Jr (1977) Use of a distant reporter group as evidence for a conformational change in a sensory receptor. Proc Natl Acad Sci USA74(5):1932-1936
35. Hahn LH, Hammes GG (1978) Structural mapping of aspartate transcarbamoylase by fl uorescence energy-transfer measurements: Determination of the distance between catalytic sites of different subunits. Biochemistry 17(12):2423-2429
36. Honda A, Adams SR, Sawyer CL et al (2001) Spatiotemporal dynamics of guanosine 3, 5 -cyclic monophosphate revealed by a genetically encoded, fl uorescent indicator. Proc Natl Acad Sci USA98(5):2437-2442
37. Sawyer CL, Honda A, Dostmann WR (2003) Cygnets: Spatial and temporal analysis of intracellular cGMP. Proc West Pharmacol Soc 46:28-31
38. Cawley SM, Sawyer CL, Brunelle KF et al (2007) Nitric oxide-evoked transient kinetics of cyclic GMP in vascular smooth muscle cells. Cell Signal 19(5):1023-1033
39. Nikolaev VO, Gambaryan S, Lohse MJ (2006) Fluorescent sensors for rapid monitoring of intracellular cGMP. Nat Methods 3(1):23-25
40. Baird GS, Zacharias DA, Tsien RY (1999) Circular permutation and receptor insertion within green fl uorescent proteins. Proc Natl Acad Sci USA96(20):11241-11246
41. Nakai J, Ohkura M, Imoto K (2001) A high signal-to-noise Ca(2+) probe composed of a single green fl uorescent protein. Nat Biotechnol 19(2):137-141
42. Nausch LW, Ledoux J, Bonev AD et al (2008) Differential patterning of cGMP in vascular smooth muscle cells revealed by single GFPlinked biosensors. Proc Natl Acad Sci USA105(1):365-370
43. Isner JC, Maathuis FJ (2011) Measurement of cellular cGMP in plant cells and tissues using the endogenous fl uorescent reporter FlincG. Plant J 65(2):329-334
44. Wood KC, Batchelor AM, Bartus K et al (2011) Picomolar nitric oxide signals from central neurons recorded using ultrasensitive detector cells. J Biol Chem 286(50):43172-43181
45. Miller CL, Cai Y, Oikawa M et al (2011) Cyclic nucleotide phosphodiesterase 1A: A key regulator of cardiacfibroblast activation and extracellular matrix remodeling in the heart. Basic Res Cardiol 106(6):1023-1039
46. Chao YC, Cheng CJ, Hsieh HT et al (2010) Guanylate cyclase-G, expressed in the Grueneberg ganglion olfactory subsystem, is activated by bicarbonate. Biochem J 432(2): 267-273
47. Tsai EJ, Kass DA (2009) Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 122(3):216-238
48. Cocks TM, Angus JA, Campbell JH et al (1985) Release and properties of endothelium-derived relaxing factor (EDRF) from endothelial cells in culture. J Cell Physiol 123(3):310-320
49. Griffith TM, Edwards DH, Lewis MJ et al (1984) The nature of endothelium-derived vascular relaxant factor. Nature 308(5960): 645-647
50. Hakim TS, Sugimori K, Camporesi EM et al (1996) Half-life of nitric oxide in aqueous solutions with and without haemoglobin. Physiol Meas 17(4):267-277
51. Keefer LK, Nims RW, Davies KM et al (1996) "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: Convenient nitric oxide dosage forms. Methods Enzymol 268:281-293
52. Griffiths C, Wykes V, Bellamy TC et al (2003) A new and simple method for delivering clamped nitric oxide concentrations in the physiological range: Application to activation of guanylyl cyclase-coupled nitric oxide receptors. Mol Pharmacol 64(6):1349-1356
53. Bellamy TC, Griffiths C, Garthwaite J (2002) Differential sensitivity of guanylyl cyclase and mitochondrial respiration to nitric oxide measured using clamped concentrations. J Biol Chem 277(35):31801-31807
54. Garthwaite J, Southam E, Boulton CL et al (1995) Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4] oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 48(2):184-188
55. Schrammel A, Behrends S, Schmidt K et al (1996) Characterization of 1H-[1,2,4] oxadiazolo[4,3-a]quinoxalin-1-one as a hemesite inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 50(1):1-5
56. Evgenov OV, Pacher P, Schmidt PM et al (2006) NO-independent stimulators and activators of soluble guanylate cyclase: Discovery and therapeutic potential. Nat Rev Drug Discov 5(9):755-768